Scientific background
The 2019-nCoV Neutralization ELISA Kit from SignalChem is an enzyme-linked immunosorbent assay meant for detecting antibodies or other molecular proteins that prevent the binding of human ACE2 and SARS-CoV-2 S1 protein in serum or other biological specimens.
Built on indirect ELISA principles, the 2019-nCoV Neutralization ELISA Kit uses recombinant human ACE2 protein coated on a 96-well plate.
Both controls and samples (with the required dilution) are blended with the 2019-nCOV S1 protein RBD-HRP and subsequently pipetted into the wells. The target neutralizing proteins or antibodies in the samples and controls will fully or partly block the binding of the S1 protein RBD-HRP to the immobilized ACE2 protein.
n 111) and contacts (
K and
L) The normalized AUC of anti-RBD IgA (K) or IgG (L) ELISA for patients with gastrointestinal (GI) symptoms (
n 32) and without GI symptoms (
n 117) was plotted. The
r and
P values for the correlations in (C) to (G) were determined by two-tailed Spearman’s correlations. For (H) to (L), horizontal bars indicate median values. Statistical significance was determined using a two-tailed Mann-Whitney
U test.
P 0.005) and severity of symptoms (
P 0.0001) but not timing of sample collection relative to onset (
P 0.69) or age (
P 0.22) (Fig. 1, C to F). Concentrations of anti-RBD IgA antibodies correlated strongly with anti-RBD IgG concentrations (